Loading
Life sciences · Journal article
Diagnostics · October 29, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background/Objectives: Peritumoral ultrasound may capture tissue characteristics relevant to treatment sensitivity. In this study, we examined whether malignancy-related prediction scores (PS) were associated with pathological response to neoadjuvant therapy in breast cancer. Methods: Support vector machine classifiers were developed for 1, 3, 5, and 7 mm peritumoral regions using 1716 pathologically confirmed lesions. We assessed PS against postoperative Miller–Payne (MP) grade in 132 patients who completed neoadjuvant therapy and surgery. Ordinal logistic regression examined overall associations, interactions with hormone receptor (HR) status and Ki67, and treatment-stratified associations adjusted for both. Holm correction addressed multiple testing. The 7 mm classifier was refitted using 1584 patients outside the response cohort while retaining the originally selected features. Results: Higher 7 mm PS was associated with lower MP grade overall (odds ratio [OR] per 0.1-unit increase, 0.79; 95% confidence interval [CI], 0.66–0.95; Holm-adjusted p = 0.048). HR and Ki67 interactions remained significant at 1 mm (adjusted p = 0.049 and 0.036, respectively). In 60 complete cases receiving chemotherapy plus anti-HER2 therapy, the original 7 mm PS was associated with MP grade after adjustment (OR, 0.60; 95% CI, 0.42–0.85; adjusted p = 0.037). The refitted PS showed an attenuated association in these patients (OR, 0.709; 95% CI, 0.526–0.955; raw p = 0.0239; Holm-adjusted p = 0.0478). Associations in the original classifier test subsets (n = 22–26) were not significant after correction. Conclusions: The 7 mm score may complement HR and Ki67 for response assessment during chemotherapy plus anti-HER2 therapy. Interactions at 1 mm suggest variation with molecular characteristics. These findings warrant independent validation.